Exclusion of constitutional p53 mutations as a cause of genetic susceptibility to colorectal cancer. by Bhagirath, T. et al.
Br. J. Cancer (1993), 68, 712 714
© Macmillan Press Ltd.,
SHORT COMMUNICATION
Exclusion of constitutional p53 mutations as a cause of genetic
susceptibility to colorectal cancer
T. Bhagirath' 3, A. Condie', M.G. Dunlop', A.H. Wyllie2 & J. Prosser'
'MRC Human Genetics Unit, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU; 2Cancer Research Campaign
Laboratories, Department ofPathology, Edinburgh University, Teviot Place, Edinburgh, EH8 9AG, UK.
There is substantial evidence to suggest that inherited predis-
position is an important factor in the incidence of colorectal
adenomas and carcinomas (reviews by Bishop & Thomas,
1990; Burt et al., 1991). The hereditary colorectal cancer
syndromes which have been most fully characterised are
familial adenomatous polyposis (FAP) and hereditary non-
polyposis colorectal cancer (HNPCC). FAP is a dominantly
inherited syndrome that results in the development of
numerous colorectal adenomatous polyps during adolescence,
some of which eventually become malignant at an early age
(Bulow, 1987). HNPCC is a clinically distinct non-polyposis
syndrome which is dominantly inherited and predisposes to
colorectal cancer at an early age without the numerous
polyps seen in FAP (Lynch et al., 1988). In addition, a
poorly defined category of non-FAP germline susceptibility
to coloretal cancer probably makes up the bulk of the genetic
input into the incidence of the disease (Dunlop, 1992).
HNPCC accounts for around 5% of all cases of colorectal
cancer, and 39% of all colorectal cancer patients below the
age of 50 (Lynch et al., 1985a; Mecklin, 1987).
A number of identified genes are known to be involved in
the development of colorectal cancer: the APC (adenomatous
polyposis coli) and MCC (mutated in colon cancer) genes in
chromosome 5q21 (Kinzler et al., 1991; Nishisho et al.,
1991), the DCC (deleted in colon cancer) gene on chromo-
some 18q (Fearon et al., 1990) and the p53 gene on
chromosome l7p13 (Baker et al., 1989). Constitutional muta-
tions in the APC gene have been shown to be the causative
genetic abnormality in FAP (Nishisho et al., 1991; Nagase et
al., 1992; Groden et al., 1993). There is some evidence for
genetic linkage to the Kidd blood group on chromosome 18q
with one large family giving a significant lod score using
Kidd blood markers (Lynch et al., 1985b). By inference, the
DCC gene which is close to the Kidd blood group locus,
might be the gene involved. However linkage to DCC has
been excluded in a number of families (Dunlop, M.G.,
unpublished data; Peltomaki et al., 1991). Notwithstanding
these findings it is possible that a minority of families may be
linked to a locus on 18q.
Recent evidence has shown that inheritance of a mutation
in the p53 gene is the primary cause for hereditary predis-
position to cancer in patients with the Li-Fraumeni syndrome
(Malkin et al., 1990; Srivastava et al., 1990), in which the
cancers characteristic of the syndrome are predominantly
breast, brain and soft tissue sarcomas, osteosarcoma,
leukaemia and adrenocortical carcinoma (Li & Fraumeni,
1969). Other cancers have been infrequently found, including
primary colon cancer (Law et al., 1991; Malkin et al., 1992).
In addition, some cancer families which are not classic
Li-Fraumeni families carry constitutional p53 mutations
(Prosser et al., 1992). While colorectal cancer is not common
in the Li-Fraumeni syndrome, somatic mutations in the p53
gene occur in a high proportion of colorectal tumours (Baker
et al., 1989; Hollstein et al., 1991). These observations
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Figure 1 A representative gel showing results with the chemical
cleavage of mismatch technique. Osmium tetroxide (OS04) and
hydroxylamine (HA) modifications are shown for fragment II,
samples 2, 3 and 4. With HA, sample 4 has bands at positions
222 bp and 306 bp, due to the codon 72 polymorphisms (de la
Calle-Martin et al., 1990) which is a G-*C change in nucleotide
12140 (HSP53G, EMBL access number XL54156). With HA,
sample 4 also has a band at 75 bp, due to a C->A change at
position 11933 in intron 3. This change is also responsible for the
453 bp band seen with OS04 in sample 4.
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Table 1 Oligonucleotides used to PCR exons 4-9 of the p53 gene.
Numbers in brackets refer to HSP53G, EMBL access number
X54156
Fragment II (Exon 4) 528 bp
5'-ACAACGTTCTGGTAAGGAC (11918-11936)
5'-CACACATTAAGTGGGTAAAC (12446-12427)
Fragment III (Exons 5 and 6) 407 bp
5'-TTCCTCTTCCTACAGTACTC (13041-13060)
5'-AGTTGCAAACCAGACCTCAG (13448-13429)
Fragment IV (Exons 7, 8 and 9) 780 bp
5'-GTGTTATCTCCTAGGTTGGC (13987-14006)
5'-AGACTTAGTACCTGAAGGGT (14766-14747)
prompted us to search for germline p53 mutations in a group
of patients who are likely to carry constitutional suscep-
tibility to colorectal cancer by nature of extremely early age
of onset.
We have identified a number of Scottish patients with
histologically confirmed non-FAP colon or rectal adenocar-
cinoma occurring under the age of 40 years. This extreme
early age of onset compares with the mean age of onset of
70.25 years in a local consecutive series of 776 patients with
colorectal cancer (data not shown). The selection criteria for
inclusion in this study were (a) age less than 30 years at
diagnosis, with or without a family history of the disease
(n = 25), and (b) age less than 40 years at diagnosis with two
or more first degree relatives affected by colorectal cancer
(n = 10). Group (b) patients therefore fulfil the empirical
criteria for classification as HNPCC. Cases due to FAP, or
arising in association with ulcerative colitis, were excluded.
There were no clinical or pathological features of the
tumours arising in the study group which distinguished them
from the local consecutive series mentioned above, including
pathological (Duke's) stage, site and degree of differentiation.
The cases with a family history were all members of site
specific colon cancer families (Lynch type I). There was no
excess of breast or gynaecological malignancies in the
relatives of the probands in which extended pedigrees of 1st
and 2nd degree kinships were ascertained and verified from
hospital records, pathology reports, cancer registration and
central public records for cause of death.
DNAs were extracted from whole blood using standard
procedures. Exons 4-9 were amplified in three segments
(Table I for oligonucleotides, their location in the p53 gene,
and fragment sizes) using polymerase chain reaction (PCR).
The PCR products were excised from TAE/low melting
agarose gels (BRL) and gene-cleaned (Stratech Scientific)
following the instruction of the manufacturer. The exons
were screened for point mutations using the technique of
chemical cleavage of mismatch, or HOT (for hydroxylamine
and osmium tetroxide used in the procedure) as described
(Cotton et al., 1988; Prosser et al., 1990, 1991).
No mutant band was observed in any of the exons of the
p53 gene in any of the individuals included in the study (see
Figure 1 for a representative result), although a number of
bands due to known polymorphisms were identified. Lynch
et al. (1992) also failed to detect constitutional mutations in
exons 5-9 of the p53 gene in 11 HNPCC pedigrees analysed
by cloning and sequencing. Exons 4-9 of the p53 gene,
which were screened in this study, have been shown to
contain more than 95% of previously identified somatic
mutations (Hollstein et al., 1991; Caron de Fromental &
Soussi, 1992), and to encompass the sites of all discovered
germline mutations, the limits being exon 4 (Toguchida et al.,
1992) and exon 9 (Malkin et al., 1992). In view of these
findings, and the high degree of sensitivity of mutation detec-
tion by the HOT technique (Condie et al., 1993), the results
of our study together with those of Lynch et al. (1992),
indicate that susceptibility to colorectal cancer is unlikely to
be conferred by constitutional p53 mutations. Even if such
mutations are present, it would be at an extremely low
frequency and they are therefore not the primary cause for
hereditary susceptibility to non-polyposis colorectal cancer
syndromes.
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